Misonix (NASDAQ:MSON) Rating Increased to C at TheStreet

Misonix (NASDAQ:MSON) was upgraded by TheStreet from a “d+” rating to a “c” rating in a note issued to investors on Tuesday, TheStreetRatingsTable reports.

MSON stock opened at $19.04 on Tuesday. The firm has a market cap of $331.14 million, a PE ratio of -13.04 and a beta of 1.48. The company has a quick ratio of 2.43, a current ratio of 3.13 and a debt-to-equity ratio of 0.26. The business has a 50 day moving average of $18.80 and a 200-day moving average of $14.57. Misonix has a 12-month low of $9.06 and a 12-month high of $20.71.

Misonix (NASDAQ:MSON) last released its earnings results on Thursday, February 4th. The medical equipment provider reported ($0.07) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.29) by $0.22. The company had revenue of $18.26 million during the quarter. Misonix had a negative return on equity of 16.94% and a negative net margin of 35.03%.

Hedge funds and other institutional investors have recently made changes to their positions in the business. Citigroup Inc. grew its holdings in Misonix by 303.1% during the fourth quarter. Citigroup Inc. now owns 2,330 shares of the medical equipment provider’s stock valued at $29,000 after purchasing an additional 1,752 shares during the period. Rhumbline Advisers grew its holdings in Misonix by 12.6% during the fourth quarter. Rhumbline Advisers now owns 13,351 shares of the medical equipment provider’s stock valued at $167,000 after purchasing an additional 1,495 shares during the period. Schonfeld Strategic Advisors LLC bought a new position in Misonix during the third quarter valued at $214,000. JPMorgan Chase & Co. grew its holdings in Misonix by 281.6% during the fourth quarter. JPMorgan Chase & Co. now owns 17,094 shares of the medical equipment provider’s stock valued at $214,000 after purchasing an additional 12,614 shares during the period. Finally, Mesirow Financial Investment Management Inc. grew its holdings in Misonix by 7.4% during the fourth quarter. Mesirow Financial Investment Management Inc. now owns 24,835 shares of the medical equipment provider’s stock valued at $310,000 after purchasing an additional 1,719 shares during the period. 41.19% of the stock is owned by institutional investors and hedge funds.

About Misonix

Misonix, Inc, together with its subsidiaries, designs, develops, manufactures, and markets minimally invasive surgical ultrasonic medical devices in the United States and internationally. The company's products include BoneScalpel, an ultrasonic bone cutting and sculpting system for surgical procedures involving the precise cutting and sculpting of bone while sparing soft tissue; SonaStar, a surgical aspirator that is used to emulsify and remove soft and hard tumors primarily in the neuro and general surgery field; and SonicOne, an ultrasonic cleansing and debridement system, which provides tissue specific debridement and cleansing of wounds and burns for the removal of devitalized tissue and fibrin deposits while sparing viable cells.

Recommended Story: Benefits of owning preferred stock